The embargo on all abstracts accepted to the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium will lift at 5:00 p.m. ET on Monday, February 25, 2019. An embargoed presscast (virtual press briefing held via teleconference and webinar) will be held at 12:00 noon ET on February 25 for credentialed media.
Attend the Meeting in Person/Participate in the Presscast
Media registration for the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium is now open. At this time, you can visit ASCO's Media Headquarters to apply for media credentials,* register to attend an upcoming meeting, access embargoed meeting information, and locate presscast dial-in information. For questions about how to navigate the site, please contact ASCO Media Registration.
*If you attended the 2018 ASCO Annual Meeting or covered the meeting remotely, you have already been credentialed by ASCO and will have access to the embargoed meeting information and the presscast. You only have to register if you want to attend the ASCO-SITC Clinical Immuno-Oncology Symposium in person in San Francisco.
Access Embargoed Information
Embargoed meeting information will be made available to credentialed media through ASCO's Media Headquarters. Once your media credentials are approved, you will receive email notifications when embargoed information has been posted.
Meet the News Planning Team
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Symposium Provides New Insights on Immunotherapy for Cancer
SAN FRANCISCO – Eight noteworthy studies exploring the implications of immuno-oncology for patient care will be presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium. The meeting will take place January 25-27 at the San Francisco Marriott Marquis in San Francisco, California. These notable abstracts discuss the efficacy of immunotherapy in rare cancers, biomarkers to predict which patients will benefit most, and managing the adverse effects of immune-based treatments. Read the full release.